Beijing Medical Insurance Bureau Announcement! The first price of the domestic COVID-19 oral drug, Cenoxin, is 750 yuan

The official website of the National Medical Products Administration announced on January 29 that it conditionally approved the marketing of the combination package of Celovir Tablets/Ritonavir Tablets and Deuterium Remdesivir Hydrobromide Tablets for the treatment of new coronavirus infection.

On January 30, the official website of the Beijing Medical Insurance Bureau announced the initial price quote for the combination package of Celosivir Tablets/Ritonavir Tablets for the treatment of COVID-19.

In accordance with the requirements of the "Notice of the Office of the National Healthcare Security Administration on Issuing the "Guidelines for the Formation of Prices of New Coronary Pneumonia Treatment Drugs (Trial)" (Medical Security Office [2023] No. 2), the relevant information on the initial quotation of the combination package of Xiannotervir Tablets/Ritonavir Tablets of Hainan Xiansheng Pharmaceutical Co., Ltd. is now publicized. The publicity period is from January 31 to February 6, 2023. If you have any objections, please submit them in your real name during the publicity period through the following methods and provide legal and valid evidence materials (the name of the unit must be stamped with the official seal). In principle, if the corresponding evidence materials are not provided, they will not be accepted.

1. Email: [email protected]

2. Letter: Office of Beijing Municipal Medical Security Bureau, 11th Floor, No. 1 West Third Ring Road South, Fengtai District, Beijing, Postal Code 100071. Please indicate “Public Opinion” on the envelope.

3. Fax: 010-89152514

Further reading

Senoxin and Pfizer's Paxlovid are drugs with the same target. According to a report by The Paper on January 29, the official WeChat account of Innovent Biologics showed that the recommended dose of Senoxin is 0.750g of Senotegravir (0.375g x 2 tablets) combined with 0.1g of ritonavir (0.1g x 1 tablet), taken orally once every 12 hours for 5 consecutive days.

In terms of mechanism of action, both Senoxin and Paxlovid are 3CL protease inhibitors. The former is a combination of Senotegravir tablets and ritonavir tablets, and the latter is a treatment method that uses namatevir and ritonavir together. Both Senotegravir and namatevir can block the activity of the new coronavirus (SARS-CoV-2). Combining them with low-dose ritonavir can help slow down the metabolism or decomposition of the former two in the body and improve the antiviral effect.

As for when it will be available for sale, Innovent said that it will be put into production immediately after the drug is approved for marketing. After the drug enters the circulation link, it will serve the needs of patients through channels such as hospitals and online Internet hospitals. In terms of price, Innovent said that as a domestically produced innovative drug with completely independent intellectual property rights, the price of Innovent will be significantly lower than Pfizer's Paxlovid, a drug with the same target, which is currently priced at 1,890 yuan.

The reporting company of Xiannuoxin is Hainan Xiansheng Pharmaceutical Co., Ltd. According to the 2021 annual report of Xiansheng Pharmaceutical Group Co., Ltd. (Xiansheng Pharmaceutical, 02096.HK), the former is a 100% holding company of Xiansheng Pharmaceutical.

Public information shows that Xiannuoxin was jointly developed by Xiansheng Pharmaceutical, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Wuhan Institute of Virology, Chinese Academy of Sciences. It is an innovative oral small molecule anti-new coronavirus drug independently developed by my country with independent intellectual property rights. On March 28 and May 13, 2022, the drug received two drug clinical trial approval notices issued by the National Medical Products Administration, respectively, for the treatment of mild and moderate new coronavirus infections and post-exposure prophylaxis for close contacts of people who have been exposed to new coronavirus positive infections.